Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company Optimer Pharmaceuticals (UNKNOWN: OPTR.DL ) rose by as much as 24% after a Bloomberg report cited that interested bidders in the company could include GlaxoSmithKline, AstraZeneca, Cubist Pharmaceuticals, and Astellas Pharma.
So what: The news of interest in Optimer -- which has one approved drug in Dificid for the treatment of Clostridium difficile-associated diarrhea -- shouldn't be any surprise as the company jumped higher in late February when it announced it had planned a strategic review for the company. According to people familiar with the matter, Optimer could draw as much as $1 billion in value. As you might imagine, not a single company was willing to comment on these "rumors."
Now what: As I said back in February, with only one drug currently on the market, any buyer would be crazy to pay a significant premium just to get their hands on Dificid. Based on the $154 million sales estimate by Wall Street in 2014, I can't imagine Dificid sales getting much past $200 million to $225 million at their peak. In short, what large pharmaceutical is going to pay more than three times peak sales for one drug? Not too many that I know of, which is why I'd suggest backing away from Optimer.
Craving more input? Start by adding Optimer Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.
While you can certainly make huge gains in biotechs like Optimer, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.